Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "SEBI"

33 News Found

Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores
News | August 20, 2021

Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores

In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y

Metropolis Healthcare gets approval for acquisition of Dr. Ganesan's Hitech Diagnostic Centre
News | July 11, 2021

Metropolis Healthcare gets approval for acquisition of Dr. Ganesan's Hitech Diagnostic Centre

In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained

Glenmark Life Sciences files for IPO
News | April 18, 2021

Glenmark Life Sciences files for IPO

The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals

Latest Stories

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging